We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.1B
1-Year Est. Return
57.92%
This Fund
S&P 500
This Quarter
Est. Return
+10.78%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$2.58B
AUM Growth
+$312M
(+14%)
Cap. Flow
+$159M
Cap. Flow
% of AUM
6.16%
Top 10 Holdings %
Top 10 Hldgs %
33.71%
Holding
96
New
19
Increased
23
Reduced
16
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$59M |
| 2 |
Stryker
SYK
|
+$39M |
| 3 |
Alkermes
ALKS
|
+$34.9M |
| 4 |
Icon
ICLR
|
+$31.7M |
| 5 |
AbbVie
ABBV
|
+$31.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
uniQure
QURE
|
+$38.8M |
| 2 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$35.7M |
| 3 |
Avantor
AVTR
|
+$28.6M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$21.7M |
| 5 |
ICU Medical
ICUI
|
+$20.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CMPS
76
Compass Pathways
CMPS
$1.53B
| $1.45M | 0.06% |
175,281
-70,783
| -29% | -$601K |
|
77
PMV Pharmaceuticals
PMVP
$59.2M
| $1.43M | 0.06% |
228,410
-189,617
| -45% | -$994K |
|
|
IOBT
78
DELISTED
IO Biotech
IOBT
| $1.2M | 0.05% |
612,713
+105,073
| +21% | +$205K |
|
79
Keros Therapeutics
KROS
$199M
| $818K | 0.03% |
20,350
| – | – |
|
|
80
uniQure
QURE
$3.03B
| $695K | 0.03% |
60,617
-2,049,453
| -97% | -$38.8M |
|
81
Sana Biotechnology
SANA
$871M
| $83.2K | ﹤0.01% |
13,966
| – | – |
|
|
82
Ascendis Pharma A/S
ASND
$16B
| – | – |
-202,115
| Closed | -$21.7M |
|
|
83
Avantor
AVTR
$9.32B
| – | – |
-1,351,326
| Closed | -$28.6M |
|
84
BioCryst Pharmaceuticals
BCRX
$2.28B
| – | – |
-2,162,411
| Closed | -$18M |
|
85
PUT
Humana
HUM
$43.7B
| – | – |
-87,900
| Closed | -$42.7M |
|
|
86
ICU Medical
ICUI
$4.21B
| – | – |
-122,703
| Closed | -$20.2M |
|
87
CALL
Eli Lilly
LLY
$1.02T
| – | – |
-39,700
| Closed | -$13.6M |
|
88
Outset Medical
OM
$84.7M
| – | – |
-21,665
| Closed | -$5.98M |
|
89
CALL
Tenet Healthcare
THC
$20.5B
| – | – |
-110,600
| Closed | -$6.57M |
|
90
PUT
UnitedHealth
UNH
$376B
| – | – |
-64,700
| Closed | -$30.6M |
|
|
MRTX
91
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-318,948
| Closed | -$11.9M |
|
|
ISEE
92
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – |
-1,465,483
| Closed | -$35.7M |
|
|
VECT
93
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| – | – |
-131,922
| Closed | -$1.12M |
|
|
BLU
94
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-439,813
| Closed | -$3.17M |
|
Similar funds
DAM
MAM
LCM
DAM
KCM
CF
MIA
YL
PFM Health Sciences's Q2 2023 Portfolio in Review
As of Q2 2023, PFM Health Sciences held 96 positions worth $2.58B, up 14% from $2.26B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
PFM Health Sciences deployed $159M of net new capital in Q2 2023, opening 19 new positions and adding to 23 existing holdings. Its largest new stake was Biogen: 198,334 shares worth $56.5M.
By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.
On the sell side, the largest reduction was uniQure, an estimated $38.8M trimmed.
- PFM Health Sciences's largest Q2 2023 buy was Biogen: 198,334 shares worth $56.5M.
- PFM Health Sciences added most to Icon in Q2 2023, an estimated $31.7M increase.
- PFM Health Sciences's biggest Q2 2023 reduction was uniQure, cutting an estimated $38.8M.
- PFM Health Sciences fully exited IVERIC bio, Inc. Common Stock in Q2 2023, selling an estimated $35.7M.
- PFM Health Sciences's ten largest holdings make up 34% of its $2.58B portfolio in Q2 2023.
- PFM Health Sciences opened 19 new positions and closed 13 in Q2 2023.
- PFM Health Sciences's portfolio value rose 14% quarter-over-quarter to $2.58B.
Based on PFM Health Sciences's 13F filing for Q2 2023, filed 14 Aug 2023.